Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1169 • ACR Convergence 2020
Three-Dimensional Analysis of Facial Asymmetry in Craniofacial Scleroderma
Daniel Glaser¹, Christopher Liu² and Kathryn Torok³, ¹UPMC Children's Hospital of Pittsburgh, Piitsburgh, PA, ²Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is a rare, progressive autoimmune disease of the skin and underlying connective tissue that can result in devastating functional impairment and cosmetic damage in children. …
Abstract Number: 1612 • ACR Convergence 2020
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Alexander Alexander¹, Mary Robichaux², Priyanka Moolchandani¹, Cristina Saez¹, Ariel Coleman³, JaLeen Rogers³, Danielle Guffey¹, Anne Dykes³, Miriah Gillispie-Taylor¹ and Tiphanie Vogel⁴, ¹Baylor College of Medicine, Houston, ²Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital, Houston, ⁴Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Pediatric rheumatology patients need effective transition from pediatric to adult providers. Texas Children’s Hospital (TCH) rheumatology clinic providers have developed a transition pathway, the…
Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Verena Balbi¹, Clovis Silva², Tatiana Pedrosa³, Rosa Pereira³, Lucia Campos³, Elaine Leon³, Nilo Duarte³, Valdemir Carvalho⁴, Sandra Pasoto³, Debora Rosario³, Leticia Brandao³, Eloisa Bonfa³ and Nadia Aikawa³, ¹Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, ²Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…
Abstract Number: 1778 • ACR Convergence 2020
Improving Teratogenic Medication Consent and Sexual Activity Screening in Adolescent and Young Females: A Pediatric Rheumatology Reproductive Health Initiative
Veronica Mruk¹, Kelly Wise², Stacy Ardoin², Edward Oberle², Stephanie Lemle³, Vidya Sivaraman⁴, Kyla Driest², Elise Berlan², Cagri Yildirim-Toruner⁵, Jackie Maher², Sarah Jones² and Fatima Barbar-Smiley⁶, ¹The Ohio State University / Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital, Columubus, OH, ⁴Nationwide Children's Hospital, Bexley, OH, ⁵Nationwide Children's Hospital, Houston, TX, ⁶Nationwide Children's Hospital/The Ohio State University, Columbus, OH
Background/Purpose: Adolescent and young women with rheumatic diseases are often prescribed teratogenic medications to manage their disease. Published reports indicate that the frequency of reproductive health counseling…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…
Abstract Number: 1171 • ACR Convergence 2020
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs², Kathryn Torok³, Maria Jose Santos⁴, Ozgur Kasapcopur⁵, Amra Adrovic⁶, Valda Stanevicha⁷, Flavio Sztajnbok⁸, Maria Teresa Terreri⁹, Ana Paula Sakamoto¹⁰, Ekaterina Alexeeva¹¹, Jordi Anton¹², Maria Katsicas¹³, Vanessa Smith¹⁴, Tadej Avcin¹⁵, Edoardo Marrani¹⁶, Mikhail Kostik¹⁷, Thomas Lehman¹⁸, Walter Alberto Sifuentes-Giraldo¹⁹, Simone Appenzeller²⁰, Mahesh Janarthanan²¹, Monika Moll²², Dana Nemcova²³, Dieneke Schonenberg-Meinema²⁴, Cristina Battagliotti²⁵, Lillemor Berntson²⁶, Blanca Bica²⁷, Jürgen Brunner²⁸, Patricia Costa Reis²⁹, Despina Eleftheriou³⁰, Liora Harel³¹, Gerd Horneff³², Tilmann Kallinich³³, Dragana Lazarevic³⁴, Kirsten Minden³⁵, Susan Nielsen³⁶, Farzana Nuruzzaman³⁷, Anjali Patwardhan³⁸, Yosef Uziel³⁹ and Nicola Helmus⁴⁰, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²Kinderklinik Heidberg Pulmologie, Hamburg, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital Garcia de Orta, Almada, Portugal, ⁵PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Federal University of São Paulo, São Paulo, Brazil, ¹⁰UNIFESP, Sao Paulo, Brazil, ¹¹Scientific Center of Children’s Health of RAMS, Moscow, Russia, ¹²Sant Joan de Déu Hospital, Madrid, Spain, ¹³Hospital de Pediatria, Buenos Aires, Argentina, ¹⁴Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ¹⁵Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁶University of Florence, Firenze, Italy, ¹⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁸Hospital for Special Surgery, New York, ¹⁹Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Unicamp, Campinas, Brazil, ²¹Sri Ramachandra University, Chennai, India, ²²University of Tübingen, Tübingen, Germany, ²³General University Hospital, Prague, Czech Republic, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁶Uppsala University Hospital, Uppsala, Sweden, ²⁷Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁸Tirol Kliniken, Innsbruck, Innsbruck, Austria, ²⁹Hospital de Santa Maria, Lisbon, Portugal, ³⁰Great Ormond Street Hospital, London, United Kingdom, ³¹Clalit Health Services, Nettnja, Israel, ³²Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³³Charite, Berlin, Germany, ³⁴KC Niš, Nis, Serbia, ³⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ³⁶Rigshospitalet, Copenhagen, Denmark, ³⁷Stony Brook Children's Hospital, Stony Brook, NY, ³⁸University of Missouri, Columbia, ³⁹Meir Medical Center, Kfar Saba, Israel, ⁴⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) has a prevalence in around 3 in a million children. Pulmonary involvement occurs in approximately 40 % in the international…
Abstract Number: 1613 • ACR Convergence 2020
Improving Transition Policy Dissemination and Care Team Communication in Pediatric Rheumatology Clinic Through Standardization of Workflow and Electronic Health Record Documentation
Rosemary Peterson¹, Emily Liebling¹, Beth Rutstein², Julie Chase¹, Atiye Bilgic Dagci³, Melissa Argraves³, Jon Burnham¹, Lisa Wiater³, Deborah Bieniakowski³, Danielle Dodson³, Jane Kennedy³, Cora Sears³ and Joyce Chang¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Morbidity and mortality increase when young adults with chronic disease transfer from pediatric to adult care. Structured healthcare transition processes improve outcomes, yet are…
Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Kelly Rouster-Stevens², Marisa Klein-Gitelman³, Karen Onel⁴, Beatrice Goilav⁵, Sonia Savani⁶, Natasha Ruth⁶, Tingting Qiu⁷, Najla Aljaberi⁸, Jianghong Deng⁹, Angela Merritt⁸, Benjamin Laskin¹⁰, Anna Carmela Sagcal-Gironella¹¹, Stacy Ardoin¹², Deborah Levy¹³, Scott Wenderfer¹⁴, Bin Huang⁷, Hermine I Brunner¹⁵ and LaUNCH Project Investigators¹⁶, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Beijing Children’s Hospital, Beijing, China (People's Republic), ¹⁰Children's Hospital of Philadelphia, Philadelphia, ¹¹Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, ¹²Nationwide Children's Hospital, Columbus, OH, ¹³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁶LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins², Kaiyu Jiang³, Susan Malkiel⁴, Betty Diamond⁴ and James Jarvis⁵, ¹Northwell LIJ Health System, Manhasset, NY, ²Northwell Health, Manhasset, ³University at Buffalo, Buffalo, NY, ⁴Northwell Health, Manhasset, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…
Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Jelena Vojinovic¹, Vyacheslav Chasnyk¹, Joke Dehoorne¹, Violeta Panaviene¹, Jonathan Akikusa², Tadej Avcin¹, Jeffrey Chaitow¹, Bernard Lauwerys¹, Jordi Antón¹, Inmaculada Penades¹, Berit Flato¹, Alina Boteanu³, Hans-Iko Huppertz¹, Juan Jaller¹, Daniela Graham⁴, Cecilia Borlenghi⁵, Bonnie Vlahos⁶, Chuanbo Zang⁶ and Nicolino Ruperto², ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Pfizer, Groton, PA, ⁵Pfizer, New York, NY, ⁶Pfizer, Collegeville, PA
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
Abstract Number: 0957 • ACR Convergence 2020
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
Bhargavi Duvvuri¹, Lauren Pachman², Richard Moore¹, Stephen Doty³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, ³The Hospital for Special Surgery, New York
Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
Abstract Number: 1172 • ACR Convergence 2020
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
Gloria Lanzoni¹, Giorgia Martini¹, Alessandra Meneghel¹, Fabio Vittadello², Biagio Castaldi¹, Elisabetta Zanatta³ and Francesco Zulian¹, ¹Department of Woman's and Child's Health, University of Padova, Padua, Italy, ²Centro Studi Statistici Explora, Padua, Italy, ³Department of Medicine-DIMED, University of Padova, Padua, Italy
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…
Abstract Number: 1614 • ACR Convergence 2020
Use of a Best Practice Alert to Encourage Transition Planning and Readiness
Bernard Danna¹, Monique Maher¹, Marietta DeGuzman², Andrea Ramirez¹, Eyal Muscal², Amanda Brown², Martha Curry², Maria Pereira², M. Brad Nelson², Pooja Patel², Ugo Awa², LeeGee Huang³, Blanca Sanchez-Fournier³, JaLeen Rogers³, Ariel Coleman³, Anne Dykes³, Miriah Gillispie-Taylor² and Tiphanie Vogel⁴, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Texas Children's Hospital, Houston, ⁴Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult care can be challenging. Patients are faced with the emotional shock of entering a new…
Abstract Number: 1680 • ACR Convergence 2020
Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Elizabeth Sloan¹ and Ayesha Zia¹, ¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The presence of antiphospholipid antibodies, including lupus anticoagulant (LA), is a risk factor for development of venous thromboembolism (VTE) in children. The impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].